Edwards Lifesciences Corp. (E1WL34)
Bovespa
113.96
0.00 (0.00%)
Closed
Oct 16, 2026
Day's Range
113.96113.96
52 wk Range
94.30122.51
Financial Statements - E1WL34 - Edwards Lifesciences Corp.
Revenue
6.06B▼ 78.6%
Net Income
1.06B▼ 95.1%Net Margin 17.6%
EBITDA
1.96B▼ 78.7%
Free Cash Flow
1.33B▼ 1.6%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 6.06B | 28.40B | 6B | 5.38B | 5.23B | 4.38B |
| Cost of Goods | 1.33B | 5.83B | 1.37B | 1.08B | 1.24B | 1.08B |
| Gross Profit | 4.73B | 22.56B | 4.62B | 4.30B | 3.98B | 3.30B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 1.63B | 7.72B | 1.72B | 1.78B | 1.58B | 1.31B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -511.70M | -169.70M | -180.10M | -38.10M | 116.20M | -407.50M |
| Pre Tax Income | 1.27B | 8.08B | 1.59B | 1.76B | 1.70B | 916.70M |
| Income Tax | 216.90M | 794.20M | 198.70M | 245.50M | 198.90M | 93.30M |
| Net Income | 1.06B | 21.77B | 1.39B | 1.52B | 1.50B | 823.40M |
| EPS Basic | 0.46 | 1.745 | 0.5775 | 0.615 | 0.6025 | 0.33 |
| EPS Diluted | 0.4575 | 1.7425 | 0.575 | 0.61 | 0.595 | 0.325 |
| Basic Shares Outstanding | 2.33B | 12.48B | 412.32M | 429.89M | 432.88M | 432.39M |
| Diluted Shares Outstanding | 2.33B | 12.48B | 412.32M | 429.89M | 432.88M | 432.39M |
| Ebit | 1.29B | 8.18B | 1.61B | 1.78B | 1.72B | 932.50M |
| Ebitda | 1.96B | 9.20B | 1.94B | 1.96B | 1.74B | 1.44B |
| Net Income Continuous Operations | 1.06B | 21.77B | 1.39B | 1.52B | 1.50B | 823.40M |
| Minority Interests | 4.10M | 4.90M | 3M | 0 | 0 | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
